Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 115 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016', provides in depth analysis on Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted pipeline therapeutics. 

The report provides comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ands scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Toll Like Receptor 4 (hToll or CD284 or TLR4) Overview 10
Therapeutics Development 11
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Stage of Development 11
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Therapy Area 12
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Indication 13
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Products Glance 16
Late Stage Products 16
Early Stage Products 17
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Companies 18
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Universities/Institutes 23
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment 25
Assessment by Monotherapy/Combination Products 25
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development 32
Batu Biologics Inc 32
BioLineRx Ltd 33
Biomedica Management Corp 34
eTheRNA Immunotherapies NV 35
Formune SL 36
GlaxoSmithKline Plc 37
Harbor Therapeutics Inc 38
Immune Design Corp 39
Immunovo BV 40
Kyorin Pharmaceutical Co Ltd 41
NovImmune SA 42
Reliance Life Sciences Pvt Ltd 43
TaiwanJ Pharmaceuticals Co Ltd 44
Vascular Biogenics Ltd 45
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles 46
ApTLR-4FT - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
BL-1110 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
C-34 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
CRX-526 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
DMT-210 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
EDA-HPVE7 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
EDA-NS3 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
EDA-TRP2 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
EDAGP-120 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
G-100 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Glyco-23 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
GSK-1795091 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
HE-3286 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
hp-91 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
ibudilast - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
ISAS-01 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
JKB-117 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
JKB-119 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
JKB-121 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
naltrexone hydrochloride - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
NI-0101 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Oligonucleotide to Activate CD40L, CD70 and TLR-4 for Oncology and Infectious Diseases - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
P-13 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
P-16 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
P-7 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
P-MAPA - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
PEPA-10 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
RSCL-0520 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
RSCL-0521 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Small Molecules to Antagonize TLR2 and TLR4 for Immunology and Inflammation - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
TWJ-201 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
VB-201 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
VB-703 - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Projects 97
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products 102
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Featured News & Press Releases 103
Dec 09, 2016: MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 27th International Symposium on ALS/MND in Dublin, Ireland 103
Dec 05, 2016: Immune Design Provides Update on Discovery Platform G100 For Intratumoral Immunotherapy 104
Nov 17, 2016: Dermata Therapeutics Announces Initiation of Treatment in a Phase 2 Atopic Dermatitis Study 104
Nov 10, 2016: MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis 105
Oct 30, 2016: MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 27th International Symposium on ALS/MND in Dublin, Ireland 105
Oct 11, 2016: MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis 106
Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients 106
Jul 13, 2016: MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS 107
Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana 108
Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate G100 At ASCO 108
May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana 109
May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study 110
Apr 21, 2016: Immune Design Announces Presentations on G-100 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 110
Apr 20, 2016: MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada 111
Apr 20, 2016: Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches at the American Association for Cancer Research (AACR) Annual Meeting 2016 112

Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 114
Disclaimer 115

List of Tables

Number of Products under Development for, H2 2016 11
Number of Products under Development by Therapy Area, H2 2016 12
Number of Products under Development by Indication, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Number of Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Development by Companies, H2 2016 (Contd..2) 21
Products under Development by Companies, H2 2016 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H2 2016 23
Products under Investigation by Universities/Institutes, H2 2016 24
Assessment by Monotherapy/Combination Products, H2 2016 25
Number of Products by Stage and Mechanism of Action, H2 2016 27
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Pipeline by Batu Biologics Inc, H2 2016 32
Pipeline by BioLineRx Ltd, H2 2016 33
Pipeline by Biomedica Management Corp, H2 2016 34
Pipeline by eTheRNA Immunotherapies NV, H2 2016 35
Pipeline by Formune SL, H2 2016 36
Pipeline by GlaxoSmithKline Plc, H2 2016 37
Pipeline by Harbor Therapeutics Inc, H2 2016 38
Pipeline by Immune Design Corp, H2 2016 39
Pipeline by Immunovo BV, H2 2016 40
Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 41
Pipeline by NovImmune SA, H2 2016 42
Pipeline by Reliance Life Sciences Pvt Ltd, H2 2016 43
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2016 44
Pipeline by Vascular Biogenics Ltd, H2 2016 45
Dormant Projects, H2 2016 97
Dormant Projects (Contd..1), H2 2016 98
Dormant Projects (Contd..2), H2 2016 99
Dormant Projects (Contd..3), H2 2016 100
Dormant Projects (Contd..4), H2 2016 101
Discontinued Products, H2 2016 102